# Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct02605772` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02605772](<https://clinicaltrials.gov/study/NCT02605772>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02605772

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02605772. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02605772, source copy `cardio:ctgov-nct02605772-2015-11-18`, retrieved 2026-10-26)
- Start date: 2015-12 (registry gives no type) (ClinicalTrials.gov record NCT02605772, source copy `cardio:ctgov-nct02605772-2015-11-18`, retrieved 2026-10-26)
- Primary completion: 2016-11 (anticipated) (ClinicalTrials.gov record NCT02605772, source copy `cardio:ctgov-nct02605772-2015-11-18`, retrieved 2026-10-26)
- Completion: 2017-03 (anticipated) (ClinicalTrials.gov record NCT02605772, source copy `cardio:ctgov-nct02605772-2015-11-18`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02605772-2015-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Acarbose
- Intervention (Drug): Metformin
- Intervention (Drug): Saxagliptin
- Lead sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: a86dc0b2868c36e962861216d4f27a4441b0a919e40f1dda8835c74f37bed6bb
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
